CSD201204 An Actual Use Study of P12 Electronic Nicotine Delivery System Among U.S. Adult Smokers

Smoking, Tobacco Clinical Trial

Official title: A Multi-Site Randomized Actual Use Study of Electronic Nicotine Delivery System (P12) Products Among Current U.S. Adult Smokers to Assess the Relative Impact of Availability and Use of Different E-liquid Flavors on Changes in Cigarette Consumption

Status Completed

Clinical Trial Summary

The purpose of this Actual Use Study (AUS) is to investigate how United States (US) adult tobacco consumers 21 to 60 years of age, inclusive, who are regular smokers (≥5 cigarettes/day on at least 20 of the past 30 days) will use the Cartridge-based ENDS investigational products (Study IP) over a 6-week Actual Use Period (AUP) in their real-life/naturalistic environments. Subjects will be able to choose freely among the Study IP available in one of the three study arms to which they are randomly assigned. The three study arms are organized by Study IP flavor categories: tobacco, menthol, and non-tobacco-non-menthol (NTNM). Subjects will self-report their ad libitum use of the Study IP as well as use of Combustible Cigarettes (CC) and any other tobacco- and nicotine-containing product (TNP) on a daily basis using an electronic diary (eDiary).

Clinical Trial Description

The AUS is a multi-site, open-label, randomized, three-arm, 8-week, prospective observational study to be conducted at multiple sites geographically dispersed within the U.S.. Adult tobacco consumers 21 to 60 years of age (inclusive) who smoked on at least 20 of the past 30 days and smoked at least 5 CPD on the days they smoked will be provided the Study IP for ad libitum use over a 6-week Actual Use Period (AUP) in their real-life/naturalistic environments. Subject-reported consumption of the Study IP, Combustible cigarettes, and other TNPs will be assessed (including, but not limited to, ENDS, smokeless tobacco, and other combustible tobacco products). The study includes pre-screening, a screening and enrollment visit (SEV), a baseline assessment period (BAP), an observational actual use period (AUP), and a close out period (COP). Following the recruitment period, the study duration per enrolled subject will be approximately eight (8) weeks. Following the administration of a Baseline Assessment Questionnaire (BAQ) at the SEV, use of Combustible Cigarettes and other TNP will be self-reported using an eDiary during the 1-week BAP. At SEV, subjects will be asked to indicate their likelihood to use each Study IP flavor variant across the three study arms. Subjects who indicate an interest in using at least one of the two flavors per arm for all three arms will be enrolled into the study and randomized into one of the three arms prior to completion of BAQ. The Study IP evaluated in this study will include the Power Unit and 12 cartridge variants (six flavor variants in two nicotine concentrations, 1.5% and 5%). In each arm, four variants (two flavor variants in two nicotine concentrations) will be available for choice. Subjects will be shown the Study IP (power unit, charging cord and all 12 flavor cartridges), user guide and handout marketing materials (MM) at SEV prior to study arm assignment. MM (poster) of Study IP in all three arms will be present at SEV and only arm-specific MM will be present at all subsequent site visits. Subjects will be first dispensed the power unit and preferred Study IP variants (i.e., specific flavor and nicotine concentrations) available within their assigned study arm during SV1 and a handout MM will be given to the subjects to take home at SV1. Starting at SV1, enrolled subjects will be able to select Study IP for use during the AUP from the Study IP available in their assigned study arm. Subjects will be instructed not to use ENDS other than the Study IP provided by the study site for the duration of the AUP in the ICF. However, if subjects report other ENDS use in the eDiary, this will not lead to study discontinuation. Subjects can use the Study IP and other TNP including Combustible Cigarettes ad libitum during the AUP and will self-report product use on a daily basis via an eDiary over the 6-week AUP. Throughout the AUP, a toll-free Hotline will be available for subjects to report potential product-related adverse health experiences, pregnancy, and/or product quality complaints. Subjects will return to the study site three additional times (SV2, SV3, and SV4) for an interview to review eDiary compliance, complete additional questionnaires, return unused Study IP, and receive additional Study IP (SV2 and SV3, as needed). At SV4, subjects will complete an End of Study Questionnaire (ESQ). The COP will allow for reporting study queries to the sites, along with possible adverse health experiences to the toll-free Hotline after SV4. Subjects will be presented with hard-copy marketing material (MM) at the SEV for all Study IP variants in all three study arms. Consistent with typical consumer marketing practices, representative point of sale (POS) MM will be present during subject interactions at the SEV and SVs (e.g., product poster). At SV1-SV4, enrolled subjects will only be exposed to MM relating to the Study IP variants for the respective study arm they are randomized into. ;

Related Conditions & MeSH terms

• Smoking, Tobacco

• NCT number: NCT05960305
• Study type: Interventional
• Source: RAI Services Company
• Status: Completed
• Phase: N/A
• Start date: September 15, 2023
• Completion date: January 28, 2024